Bayer receives FDA approval for SUNHARBO, a Factor XIa inhibitor for secondary stroke prevention
The U.S. Food and Drug Administration approved Bayer’s oral Factor XIa inhibitor SUNHARBO (asundexian) for use with antiplatelet therapy in adults who have had a recent non‑cardioembolic ischemic stroke or a high‑risk transient ischemic attack. The decision was based on the Phase 3 OCEANIC‑STROKE trial, which showed a lower ischemic‑stroke rate with SUNHARBO. Bayer expects the drug to ship in the United States in mid‑to‑late November 2026.
Why it matters
The approval allows Bayer to commercialise its first‑in‑class Factor XIa inhibitor in the U.S., creating a new revenue stream once the product ships. The company’s launch timeline suggests sales could begin shortly after the mid‑to‑late‑November shipment.
Key facts
- 1The FDA approved SUNHARBO for secondary stroke prevention in the United States. tradingview.com
- 2In the Phase 3 OCEANIC‑STROKE trial, ischemic stroke occurred in 6.2% of patients receiving SUNHARBO versus 8.4% with placebo, a hazard ratio of 0.74. tradingview.com
- 3The trial randomised 12,327 patients, with 6,162 assigned to SUNHARBO and 6,165 to placebo. rttnews.com
- 4SUNHARBO reduced ischemic stroke by 26% compared with placebo (6.2% vs 8.4%). rttnews.com
- 5The recommended dosage is 50 mg once daily. rttnews.com
- 6Bayer expects U.S. shipping to begin in mid‑to‑late November 2026. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.